The Central Board of the Indonesian Society of Neurosurgeons (PERSPEBSI) visited the Dexa Laboratories of Biomolecular Sciences (DLBS) and the Dexa Site Cikarang Manufacturing (DSCM) in Cikarang, West Java, on Saturday, May 18, 2024. This visit aimed to showcase Dexa's facilities to the doctors, enhancing their confidence in the quality upheld by Dexa Group.
Ellsa Maria, Production DSC Manager at DSCM, and Mr. Laurentius Haryanto, Group Research Innovation & Invention Manager at DLBS, welcomed the visit.
During the visit, the doctors were given a direct tour of DLBS's research facilities, highlighting Dexa Group's strong commitment to research and development. They were also introduced to DSCM's facilities, which demonstrated the high-quality manufacturing processes employed by Dexa Group.
The tour also featured Indonesian Indigenous Modern Medicines (Obat Modern Asli Indonesia (OMAI)) products, developed through rigorous research by DLBS scientists and manufactured by DSCM, showcasing Dexa Group's technological advancements.
This initiative was designed to strengthen doctors' trust in Dexa's products, which are the result of advanced research and high-tech production processes.
"Through this visit, we hope Dexa Medica's OMAI and health supplements will gain wider acceptance in hospitals and foster trust among doctors," said Ms. Ellsa.
Mr. Laurentius added, "This is a valuable opportunity for doctors to see Dexa's comprehensive facilities, from research to commercial production. It proves Dexa's dedication to OMAI."
This visit is expected to solidify relationships further and build confidence among doctors in the high quality of Dexa Group's products, which have undergone stringent and innovative research processes.
